Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. Among authors: boccomini c. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Novak U, et al. Among authors: boccomini c. EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781158 Free PMC article.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Among authors: boccomini c. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Ladetto M, et al. Among authors: boccomini c. Ann Oncol. 2024 Jan;35(1):118-129. doi: 10.1016/j.annonc.2023.10.095. Epub 2023 Nov 3. Ann Oncol. 2024. PMID: 37922989 Free article. Clinical Trial.
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial.
Ferrero S, Grimaldi D, Arrigoni E, Pironti M, Zaccaria GM, Alessandria B, Genuardi E, De Luca G, Ghislieri M, Tavarozzi R, Di Rocco A, Re A, Stefoni V, Cavallo F, Boccomini C, Balzarotti M, Zilioli V, Moita F, Arcaini L, Lucchini E, Ballerini F, Ferreri AJM, Puccini B, Palumbo GA, Galimberti S, Cortelazzo S, Di Paolo A, Ladetto M. Ferrero S, et al. Among authors: boccomini c. Blood Adv. 2023 Jul 25;7(14):3764-3774. doi: 10.1182/bloodadvances.2022009504. Blood Adv. 2023. PMID: 37058477 Free PMC article. Clinical Trial.
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi.
Margiotta-Casaluci G, Bigliardi S, Cocito F, Meli E, Petrucci L, Nicolosi M, Annibali O, Boccomini C, Bozzoli V, Castellino A, Cattina F, Cenfra N, Ciavarella S, Kovalchuk S, Rotondo F, Fama A, Olivieri J, Zaja F. Margiotta-Casaluci G, et al. Among authors: boccomini c. Front Oncol. 2023 Mar 10;13:1120967. doi: 10.3389/fonc.2023.1120967. eCollection 2023. Front Oncol. 2023. PMID: 36969038 Free PMC article.
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, Castellino C, Stefoni V, Pinto A, Zanni M, Ciancia R, Ghiggi C, Rossi FG, Arcari A, Ilariucci F, Zilioli VR, Flenghi L, Celli M, Volpetti S, Benedetti F, Ballerini F, Musuraca G, Bruna R, Patti C, Leonardi F, Arcaini L, Magagnoli M, Cavallo F, Bermema A, Tucci A, Boccomini C, Ciccone G, Carniti C, Pileri SA, Corradini P. Chiappella A, et al. Among authors: boccomini c. Leukemia. 2023 Feb;37(2):433-440. doi: 10.1038/s41375-022-01780-1. Epub 2023 Jan 18. Leukemia. 2023. PMID: 36653509 Free PMC article. Clinical Trial.
Phase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ribrag V, Chavez JC, Boccomini C, Kaplan J, Chandler JC, Santoro A, Corradini P, Flinn IW, Advani R, Cassier PA, Sangha R, Kenkre VP, Isufi I, Uttamsingh S, Hagner PR, Gandhi AK, Shen F, Michelliza S, Haeske H, Hege K, Pourdehnad M, Kuruvilla J. Ribrag V, et al. Among authors: boccomini c. EJHaem. 2022 Jan 14;3(1):139-153. doi: 10.1002/jha2.375. eCollection 2022 Feb. EJHaem. 2022. PMID: 35846221 Free PMC article.
Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.
Nastoupil LJ, Kuruvilla J, Chavez JC, Bijou F, Witzig TE, Santoro A, Flinn IW, Boccomini C, Kenkre VP, Corradini P, Isufi I, Andorsky DJ, Klein LM, Greenwald DR, Sangha R, Shen F, Hagner P, Li Y, Dobmeyer J, Gong N, Uttamsingh S, Pourdehnad M, Ribrag V. Nastoupil LJ, et al. Among authors: boccomini c. EJHaem. 2022 Feb 14;3(2):394-405. doi: 10.1002/jha2.394. eCollection 2022 May. EJHaem. 2022. PMID: 35846031 Free PMC article.
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, Skrypets T, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. Luminari S, et al. Among authors: boccomini c. J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28. J Clin Oncol. 2022. PMID: 34709880 Clinical Trial.
33 results